论文部分内容阅读
我院自1989年6月～1993年6月间,应用VDD方案(长春新碱、柔红霉素和地塞米松)治疗难治性和复发性多发性骨髓瘤12例。结果血清单株免疫球蛋白下降75％以上者4例,下降50％～75％者4例,总有效率66.7％,平均用药44天显效,持续有效7.1个月,副作用较小。现报告如下。 1 临床资料 1.1 一般临床资料 诊断标准采用Greipp提出的诊断标准。免疫分型:IgG型7例,IgA型4例,IgM型1例。年龄50岁～68岁,平均62岁,男10例,女2例。治疗前均有化疗史3.5～10个月,平均6.5个月,其中2例COP方案,2例M_2方案治疗无效;6例COP方案,2例M_2方案治疗后复发。
In our hospital from June 1989 to June 1993, 12 patients with refractory and relapsed multiple myeloma were treated with VDD regimen (vincristine, daunorubicin, and dexamethasone). Results 4 cases of serum immunoglobulin decreased by more than 75%, 40% decreased by 50% to 75%, and the total effective rate was 66.7%. The average effective medication was 44 days, effective for 7.1 months, and the side effects were small. The report is as follows. 1 Clinical data 1.1 General clinical data The diagnostic criteria adopted the diagnostic criteria proposed by Greipp. Immunophenotyping: 7 cases of IgG, 4 cases of IgA, and 1 case of IgM. Aged 50 to 68 years old, average 62 years old, 10 males and 2 females. Before treatment, there was a history of 3.5 to 10 months of chemotherapy, with an average of 6.5 months. Two of the patients had COP and 2 had M_2 regimen; 6 had COP and 2 had recurrence after treatment.